Active roles of tumor stroma in breast cancer metastasis.

Department of Chemistry and Biochemistry and Institute of Molecular Biophysics, Florida State University, Tallahassee, FL 32306-4390, USA.
International journal of breast cancer 01/2012; 2012:574025. DOI: 10.1155/2012/574025
Source: PubMed

ABSTRACT Metastasis is the major cause of death for breast cancer patients. Tumors are heterogenous cellular entities composed of cancer cells and cells of the microenvironment in which they reside. A reciprocal dynamic interaction occurs between the tumor cells and their surrounding stroma under physiological and pathological conditions. This tumor-host communication interface mediates the escape of tumor cells at the primary site, survival of circulating cancer cells in the vasculature, and growth of metastatic cancer at secondary site. Each step of the metastatic process is accompanied by recruitment of stromal cells from the microenvironment and production of unique array of growth factors and chemokines. Stromal microenvironment may play active roles in breast cancer metastasis. Elucidating the types of cells recruited and signal pathways involved in the crosstalk between tumor cells and stromal cells will help identify novel strategies for cotargeting cancer cells and tumor stromal cells to suppress metastasis and improve patient outcome.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epithelial-mesenchymal transition (EMT) is a highly conserved morphogenic process defined by the loss of epithelial characteristics and the acquisition of a mesenchymal phenotype. EMT is associated with increased aggressiveness, invasiveness, and metastatic potential in carcinoma cells. To assess the contribution of extracellular vesicles during EMT, we conducted a proteomic analysis of exosomes released from Madin Darby canine kidney (MDCK) cells, and MDCK cells transformed with oncogenic H-Ras (21D1 cells). Exosomes are 40 to 100 nm membranous vesicles originating from the inward budding of late endosomes and multivesicular bodies (MVBs) and are released from cells upon fusion of MVBs with the plasma membrane. Exosomes from MDCK cells (MDCK Exos) and 21D1 cells (21D1Exos) were purified from cell culture media using density gradient centrifugation (OptiPrep), and protein content identified by GeLC MS/MS proteomic profiling. Both MDCK- and 21D1-Exos populations were morphologically similar by cryoelectron microscopy and contained stereotypical exosomes marker proteins such as TSG101, Alix and CD63. In this study we show that the expression levels of typical EMT hallmark proteins seen in whole cells correlate with those observed in MDCKExos and 21D1Exos; i.e., reduction of characteristic inhibitor of angiogenesis, thrombospondin1 and epithelial markers Ecadherin, and EpCAM, with a concomitant up-regulation of mesenchymal makers such as vimentin. Further, we reveal that 21D1Exos are enriched with several proteases (e.g., MMP1, MMP14, MMP19, ADAM10, ADAMTS1), and integrins (e.g., ITGB1, ITGA3, ITGA6) that have been recently implicated in regulating the tumour microenvironment to promote metastatic progression. A salient finding of this study was the unique presence of key transcriptional regulators (e.g., the master transcriptional regulator YXB1) and core splicing complex components (e.g., SF3B1, SF3B3 and SFRS1) in mesenchymal 21D1Exos. Taken together, our findings reveal that exosomes from Ras-transformed MDCK cells are reprogrammed with factors which may be capable of inducing EMT in recipient cells.
    Molecular &amp Cellular Proteomics 05/2013; · 7.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Solid tumors are embedded in a stromal microenvironment consisting of immune cells, such as macrophages and lymphocytes, as well as nonimmune cells, such as endothelial cells and fibroblasts. Chemokines are a type of small secreted chemotactic cytokine and together with their receptors play key roles in the immune defense. Critically, they regulate cancer cellular migration and also contribute to their proliferation and survival. The CCR5 chemokine receptor is involved in leucocytes chemotaxis to sites of inflammation and plays an important role in the macrophages, T cells, and monocytes recruitment. Additionally, CCR5 may have an indirect effect on cancer progression by controlling the antitumor immune response, since it has been demonstrated that its expression could promote tumor growth and contribute to tumor metastasis, in different types of malignant tumors. Furthermore, it was demonstrated that a CCR5 antagonist may inhibit tumor growth, consisting of a possible therapeutic target. In this context, the present review focuses on the establishment of CCR5 within the interface of host immunity, tumor microenvironment, and its potential as a targeting to immunotherapy.
    Disease markers 01/2014; 2014:126954. · 2.14 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic interventions that target critical elements of the tumor stromal microenvironment may improve blockades to metastatic progression. Here we report characterization of a mechanism that address this opportunity, based on studies of the polyoma middle T-induced mouse model of mammary carcinoma that exhibits aggressive metastases due to lack of the type II TGF-ß receptor (PyMTmgko mice). We hypothesized that PyMTmgko-activated stroma interacts with carcinoma cells to promote invasion and metastasis. Extracellular matrix associated with PyMTmgko tumors was found to exhibit increased stiffness, fibrillar collagen levels and expression of the collagen crosslinking enzyme lysyl oxidase (LOX), compared to polyoma middle T-induced mammary carcinomas in mice expressing the type II TGF-ß receptor (PyMTfl/fl). Inhibiting LOX activity in PyMTmgko mice had no effect on tumor latency or size, but decreased tumor metastasis by inhibiting tumor cell intravasation. This phenotype was associated with a decrease in keratin 14-positive myoepithelial cells in PyMTmgko tumors following LOX inhibition along with a decrease in focal adhesion formation. Interestingly, the primary source of LOX was determined to be activated fibroblasts. LOX expression was driven at this site by myeloid cell-derived TGF-ß, which is linked to human breast cancer. Our results suggested that stromal expansion in PyMTmgko tumors was elicited by immune cell infiltrates that promoted fibroblast activation, leading to metastatic behavior by modulating phenotypic characteristics of basal epithelial cells. More broadly, these findings argue that microenvironmental changes triggered by epithelial cells can drive tumor pathogenicity and offer important therapeutic targets to inhibit metastasis.
    Cancer Research 07/2013; · 9.28 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014